Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550920 | 1.00 | POLB (0.60) | POLBLMNASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL27645361 | 0.83 | POLB (0.46) | POLBLMNASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL30441012 | 0.81 | KDM4E (0.46) | POLBLMNATDP1L3MBTL1ALDH1A1 | |
| SCHEMBL163493 | 0.81 | POLB (0.45) | POLBLMNASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL2633213 | 0.81 | P2RX7 (0.56) | POLBLMNASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL624343 | 0.81 | LMNA (0.61) | POLBLMNASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL29412879 | 0.81 | LMNA (0.61) | POLBLMNASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL9837285 | 0.81 | POLB (0.45) | POLBLMNASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL8422472 | 0.80 | POLB (0.44) | POLBLMNASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL1292847 | 0.80 | NAPRT (0.56) | POLBTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213547-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2025-07-03 | — | — | US | disclosed |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-117843619-A | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and methods for preparing the modulators | 弗特克斯药品有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-110267948-B | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and methods for preparing the modulators | 弗特克斯药品有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023175591-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | WO | disclosed |
| CN-115872926-A | Preparation method of triazole antifungal drug and intermediate thereof | 南通诺泰生物医药技术有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-115772121-A | Preparation method of 2-methylamino-3-hydroxymethylpyridine | 南通诺泰生物医药技术有限公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-20 | — | — | US | disclosed |
| CN-109803962-B | Modulators of cystic fibrosis transmembrane conductance regulator proteins, and pharmaceutical compositions | 弗特克斯药品有限公司 | 2022-04-29 | — | — | CN | disclosed |
| US-6812238-B1 | WATER SOLUBLE FUNGICIDES FOR SYSTEMIC MYCOSES; ORAL AND PARENTERAL ADMINISTRATION | BASILEA PHARMACEUTICA AG (CH) | 2004-11-02 | — | — | US | disclosed |
| US-6812238-B1 | WATER SOLUBLE FUNGICIDES FOR SYSTEMIC MYCOSES; ORAL AND PARENTERAL ADMINISTRATION | BASILEA PHARMACEUTICA AG (CH) | 2004-11-02 | — | — | US | disclosed |
| US-6562844-B2 | Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-6531470-B1 | Antimicrobial compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-11 | — | — | US | disclosed |
| EP-1280795-A2 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| US-20020183371-A1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | GORDEEV MIKHAIL F (US) | 2002-12-05 | — | — | US | disclosed |
| US-6239152-B1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| WO-2001032652-A2 | N-SUBSTITUTED CARBAMOYLOXYALKYL-AZOLIUM DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2001-05-10 | — | — | WO | disclosed |
| EP-1049682-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | Versicor, Inc. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037630-A1 | OXAZOLIDINONE COMBINATORIAL LIBRARIES, COMPOSITIONS AND METHODS OF PREPARATION | VERSICOR, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183371-A1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PAICS, CDK4, OXA1L | POLB 307/4885LMNA 1648/4885SMN1; SMN2 154/4885 |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | POLB 3834/4885LMNA 3944/4885SMN1; SMN2 4573/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | POLB 3834/4885LMNA 3944/4885SMN1; SMN2 4573/4885 |
| US-20250213547-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES | SMN1; SMN2, PMP22, GBA2 | POLB 2602/4885LMNA 2937/4885SMN1; SMN2 1/4885 |
| US-11447449-B2 | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use | IDO1, IDO2, INMT | POLB 1958/4885LMNA 4537/4885SMN1; SMN2 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.